-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Raises Price Target to $7

Benzinga·03/24/2025 11:43:46
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and raises the price target from $6 to $7.